EGRX Eagle Pharmaceuticals Inc

Price (delayed)

$21.53

Market cap

$281.86M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.21

Enterprise value

$336.29M

Eagle Pharmaceuticals Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements ...

Highlights

The company's equity rose by 12% YoY and by 4% QoQ

Eagle Pharmaceuticals's quick ratio has decreased by 29% YoY but it has increased by 22% from the previous quarter

The company's revenue fell by 16% QoQ but it rose by 8% YoY

The EPS has plunged by 108% from the previous quarter and by 107% YoY

The net income has dropped by 107% since the previous quarter and by 107% year-on-year

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: http://www.eagleus.com

Peers: JNJ TEVA AMGN LLY

Key stats

What are the main financial stats of EGRX

Market

Shares outstanding

13.09M

Market cap

$281.86M

Enterprise value

$336.29M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

1.16

Price to sales (P/S)

1.05

EV/EBIT

17.52

EV/EBITDA

9.05

EV/Sales

1.26

Earnings

Revenue

$267.04M

EBIT

$19.2M

EBITDA

$37.16M

Free cash flow

$33.73M

Per share

EPS

-$0.21

Free cash flow per share

$2.58

Book value per share

$18.56

Revenue per share

$20.45

TBVPS

$19.62

Balance sheet

Total assets

$414.18M

Total liabilities

$171.33M

Debt

$76.33M

Equity

$242.85M

Working capital

$94.68M

Liquidity

Debt to equity

0.31

Current ratio

1.97

Quick ratio

1.4

Net debt/EBITDA

1.46

Margins

EBITDA margin

13.9%

Gross margin

68.4%

Net margin

-1%

Operating margin

12.3%

Efficiency

Return on assets

-0.7%

Return on equity

-1.1%

Return on invested capital

12%

Return on capital employed

6.1%

Return on sales

7.2%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

EGRX stock price

How has the Eagle Pharmaceuticals stock price performed over time

Intraday

4.01%

1 week

5.28%

1 month

-23.63%

1 year

-53.23%

YTD

-26.34%

QTD

-24.11%

Financial performance

How have Eagle Pharmaceuticals's revenue and profit performed over time

Revenue

$267.04M

Gross profit

$182.56M

Operating income

$32.9M

Net income

-$2.67M

Gross margin

68.4%

Net margin

-1%

Eagle Pharmaceuticals's net margin has shrunk by 109% QoQ and by 107% YoY

The net income has dropped by 107% since the previous quarter and by 107% year-on-year

Eagle Pharmaceuticals's operating income has shrunk by 59% QoQ and by 50% YoY

The operating margin has dropped by 54% year-on-year and by 52% since the previous quarter

Growth

What is Eagle Pharmaceuticals's growth rate over time

Valuation

What is Eagle Pharmaceuticals stock price valuation

P/E

N/A

P/B

1.16

P/S

1.05

EV/EBIT

17.52

EV/EBITDA

9.05

EV/Sales

1.26

The EPS has plunged by 108% from the previous quarter and by 107% YoY

EGRX's P/B is 67% below its 5-year quarterly average of 3.5 and 36% below its last 4 quarters average of 1.8

The company's equity rose by 12% YoY and by 4% QoQ

EGRX's price to sales (P/S) is 67% lower than its 5-year quarterly average of 3.2 and 30% lower than its last 4 quarters average of 1.5

The company's revenue fell by 16% QoQ but it rose by 8% YoY

Efficiency

How efficient is Eagle Pharmaceuticals business performance

Eagle Pharmaceuticals's ROA has plunged by 107% from the previous quarter and by 105% YoY

Eagle Pharmaceuticals's return on equity has shrunk by 107% QoQ and by 106% YoY

EGRX's return on invested capital has dropped by 80% year-on-year and by 75% since the previous quarter

The ROS has plunged by 67% YoY and by 65% from the previous quarter

Dividends

What is EGRX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EGRX.

Financial health

How did Eagle Pharmaceuticals financials performed over time

Eagle Pharmaceuticals's total assets is 142% higher than its total liabilities

The total liabilities has soared by 64% year-on-year

Eagle Pharmaceuticals's quick ratio has decreased by 29% YoY but it has increased by 22% from the previous quarter

Eagle Pharmaceuticals's debt is 69% lower than its equity

Eagle Pharmaceuticals's debt to equity has soared by 182% YoY and by 15% from the previous quarter

Eagle Pharmaceuticals's debt has increased by 22% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.